List of Excipients in Branded Drug ACCRUFER

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Shield TX (UK) Ltd	ACCRUFER	ferric maltol	73059-001	CROSPOVIDONE	2028-12-19
Shield TX (UK) Ltd	ACCRUFER	ferric maltol	73059-001	FD&C BLUE NO. 1	2028-12-19
Shield TX (UK) Ltd	ACCRUFER	ferric maltol	73059-001	FD&C RED NO. 40	2028-12-19
Shield TX (UK) Ltd	ACCRUFER	ferric maltol	73059-001	FD&C YELLOW NO. 6	2028-12-19
Shield TX (UK) Ltd	ACCRUFER	ferric maltol	73059-001	HYPROMELLOSES	2028-12-19

ACCRUFER Excipient Strategy and Commercial Opportunities

Last updated: August 5, 2026

ACCRUFER, an oral ferric maltol capsule marketed by Shield Therapeutics, uses a relatively simple immediate-release formulation to deliver 30 mg of elemental iron twice daily. Its commercial opportunity is concentrated in iron-deficiency anemia patients who cannot tolerate or adequately absorb conventional ferrous salts, including patients with chronic kidney disease and inflammatory bowel disease. The formulation strategy prioritizes iron complex stability, gastrointestinal tolerability, manufacturing reproducibility, and regulatory familiarity rather than complex delivery technology.

The main excipient opportunities are formulation optimization, alternate capsule-shell systems, global excipient harmonization, supply-chain redundancy, and lifecycle products that preserve ferric maltol while improving adherence or administration.

What is ACCRUFER and how is it formulated?

ACCRUFER contains ferric maltol, an iron(III)-maltol complex. Each hard capsule provides 30 mg of elemental iron. The FDA-approved regimen is one capsule twice daily on an empty stomach, at least one hour before or two hours after food. The product is an immediate-release oral capsule, not a delayed-release, enteric-coated, sustained-release, or injectable product.[1]

Product attribute	ACCRUFER specification
Active ingredient	Ferric maltol
Elemental iron strength	30 mg per capsule
Dosage form	Immediate-release hard capsule
FDA approval	July 25, 2019
U.S. sponsor	Shield Therapeutics, through its U.S. commercial operations
Therapeutic category	Oral iron replacement
Primary use	Iron deficiency in adults
Administration	Twice daily on an empty stomach
Principal formulation objective	Deliver absorbable iron while reducing gastrointestinal burden associated with some ferrous salts

The formulation contains ferric maltol together with conventional solid-dose excipients. FDA labeling identifies excipients in the capsule formulation and shell, including commonly used materials such as crospovidone, magnesium stearate, sodium lauryl sulfate, talc, gelatin, titanium dioxide, and colorants. The approved label remains the controlling source for the exact qualitative composition and any manufacturing-specific grades.[1]

What excipient strategy does ACCRUFER use?

ACCRUFER uses a conventional capsule platform with targeted excipient functions.

Ferric maltol stabilization

Ferric maltol is a coordination complex rather than a simple inorganic iron salt. The formulation must preserve the ferric iron-maltol association through blending, encapsulation, storage, and dissolution. Excipient selection therefore requires control of:

• Water activity and residual moisture.
• Local pH effects.
• Redox-active impurities.
• Metal contamination.
• Excipient peroxide levels.
• Interaction with capsule-shell materials.
• Long-term assay and related-substance stability.

Low-moisture excipients and controlled storage conditions can be commercially important even where they are not independently patent-protected. Suppliers that can provide consistent particle size, low peroxide content, and tight elemental impurity specifications have a stronger position than commodity suppliers.

Immediate-release disintegration

Crospovidone can support rapid capsule-content dispersion. The formulation does not need the polymer architecture associated with modified-release systems. This simplifies scale-up, but it places greater importance on powder wetting, blend uniformity, capsule fill performance, and dissolution reproducibility.

Lubrication and manufacturing flow

Magnesium stearate supports capsule-filling and powder-flow performance. Excessive lubrication can slow wetting or dissolution, while insufficient lubrication can increase ejection force, weight variability, and equipment fouling. A commercial reformulation would need to show that changes in lubricant concentration or mixing time do not alter ferric maltol release or stability.

Surfactant and wetting performance

Sodium lauryl sulfate can improve wetting of hydrophobic or poorly wettable powder components. Its use creates a formulation trade-off. Increasing surfactant concentration may improve dissolution but can affect gastrointestinal tolerability, powder behavior, and regulatory justification. A lower-irritancy surfactant or surfactant-free design could have commercial value if it maintains dissolution and stability.

Capsule-shell control

The capsule shell affects moisture transmission, appearance, supply continuity, and patient acceptability. Gelatin provides a familiar platform, but hydroxypropyl methylcellulose and other vegetarian capsules could support regional or patient-segment positioning. A shell change would require compatibility, dissolution, stability, and bioequivalence work.

Which excipients create the strongest commercial opportunities?

The largest near-term opportunity is not a new excipient molecule. It is a qualified, reliable excipient system that reduces manufacturing risk and supports differentiated dosage forms.

Opportunity	Technical rationale	Commercial value
Low-moisture capsule shell	Limits moisture-driven degradation and fill variability	Supports global supply and stability
HPMC capsule conversion	Addresses vegetarian, religious, and regional requirements	Expands patient and market access
Alternative disintegrant	May improve dissolution or reduce formulation dependence on current suppliers	Creates second-source flexibility
Surfactant replacement	May improve tolerability or simplify excipient labeling	Supports reformulation claims
Direct-compression grade excipients	Improves scale-up and manufacturing efficiency	Reduces cost of goods
Excipient premix	Controls blend uniformity and process variability	Helps contract manufacturing
Low-peroxide excipients	Reduces oxidative degradation risk	Strengthens stability package
Pediatric-friendly multiparticulates	Enables flexible dosing and swallowing	Opens pediatric and geriatric segments
Sprinkle or sachet formulation	Improves administration for dysphagia patients	Extends product lifecycle
Fixed-dose combination platform	Could combine iron with disease-specific therapy	Creates higher-value specialty products

Excipient suppliers should focus on documented pharmaceutical-grade consistency, extractables and leachables control, elemental impurity data, and global regulatory support. The product is unlikely to reward an excipient that only reduces unit cost. It can reward an excipient that improves stability, tolerability, or administration without changing the clinical profile.

What formulations are protected by ACCRUFER-related intellectual property?

The central intellectual-property position is associated with ferric maltol compositions and their therapeutic use. The relevant protection is broader than the identity of any individual excipient. A generic manufacturer could face risk from claims directed to:

• Ferric maltol pharmaceutical compositions.
• Oral dosage forms containing ferric maltol.
• Treatment of iron deficiency or iron-deficiency anemia.
• Dosing regimens involving ferric maltol.
• Formulation and manufacturing parameters.
• Stability or purity characteristics, where claimed.

A formulation that substitutes crospovidone, changes the capsule shell, or removes sodium lauryl sulfate may still fall within composition or method-of-use claims. Excipient substitution is therefore not automatically a design-around.

The U.S. product is subject to FDA patent-listing and generic-certification rules. ACCRUFER's new-chemical-entity exclusivity began with the 2019 approval and ran for five years, subject to FDA regulatory conventions. Patent protection, if listed and enforceable, can extend beyond that period.[1,2]

How strong is the ACCRUFER patent estate?

The estate is commercially relevant because ferric maltol is a differentiated iron complex, while the dosage form is a conventional capsule. That structure creates a mixed defensive profile:

• Active-complex claims can be stronger against direct substitutions that retain ferric maltol.
• Method-of-use claims may be important where treatment populations and dosing instructions are specific.
• Conventional capsule excipient claims are generally more vulnerable to formulation changes unless the claims define a narrow but critical composition.
• Manufacturing claims can create barriers where purity, complex formation, or process control is difficult to reproduce.

The practical strength of the estate depends on the live Orange Book listings, patent claim scope, terminal disclaimers, patent-term adjustments, prosecution history, and any pending or resolved Paragraph IV litigation. A patent number should not be treated as an enforceable barrier without reviewing its issued claims and current legal status.

When does ACCRUFER lose exclusivity?

ACCRUFER's five-year NCE exclusivity period has expired. That does not establish immediate generic entry. A generic applicant must still address listed patents and may file an ANDA with Paragraph III or Paragraph IV certifications.

Exclusivity or barrier	ACCRUFER position
FDA approval	2019
Five-year NCE exclusivity	Expired in 2024
Orphan-drug exclusivity	Not the principal U.S. protection identified for the product
Patent protection	Depends on listed patents, expiration dates, and enforceability
Generic pathway	ANDA, subject to patent certifications
Biosimilar pathway	Not applicable because ferric maltol is a small molecule
Pediatric exclusivity	Must be confirmed through current FDA records rather than assumed

The commercial loss-of-exclusivity date is therefore a patent-driven event, not the NCE-exclusivity expiration date. The first credible generic launch risk arises when a manufacturer has both an approvable ANDA and a viable pathway through listed patents.

What is the Orange Book status of ACCRUFER?

The Orange Book is the controlling source for current U.S. patent listings, expiration dates, exclusivity codes, and reference-product information. ACCRUFER should be reviewed under its FDA product identifier and active ingredient, ferric maltol.

Orange Book analysis should distinguish:

1. Patents listed by the sponsor.
2. Patents that remain unexpired.
3. Patents relevant to the proposed generic's label.
4. Patents subject to Paragraph IV certification.
5. Patents that may be challenged through litigation.
6. Regulatory exclusivity that has already expired.

A listed method-of-use patent may not block a generic applicant that carves the patented indication from its label, provided the remaining label is legally and clinically viable. A composition patent is generally harder to avoid through a label carve-out.

Which companies are challenging ACCRUFER?

Public generic-entry risk should be evaluated through FDA ANDA activity, Paragraph IV notices, federal district-court filings, and Shield Therapeutics' securities disclosures. Company names should not be inferred from ordinary market competition or distributor activity.

The relevant challengers are companies that have:

• Filed an ANDA referencing ACCRUFER.
• Sent a valid Paragraph IV notice.
• Triggered patent litigation.
• Obtained a court ruling or settlement.
• Disclosed a launch strategy.

No biosimilar challenger is relevant. Ferric maltol is a chemically defined small molecule, so the competitive pathway is generic substitution rather than biosimilar interchangeability.

What patent litigation and settlements affect ACCRUFER?

A Paragraph IV notice can trigger a 45-day period for the patent owner to file suit. A timely suit can impose a 30-month stay on FDA approval, subject to statutory exceptions and court decisions. The stay does not guarantee patent validity or prevent an authorized generic or other non-ANDA competition.

Settlement terms may address:

• Earliest generic launch.
• Patent expiration.
• Authorized-generic supply.
• Royalty obligations.
• Restricted indication labeling.
• No-admission provisions.
• Manufacturing or licensing rights.

Settlement agreements can materially change the market-entry date even when the underlying patent remains listed. Companies evaluating ACCRUFER should therefore review court dockets, FDA patent records, and sponsor disclosures together rather than relying on the Orange Book alone.

How does ACCRUFER compare with conventional oral iron products?

ACCRUFER competes with low-cost ferrous sulfate, ferrous fumarate, ferrous gluconate, intravenous iron, and disease-specific treatment strategies.

Attribute	ACCRUFER	Ferrous salts	Intravenous iron
Active iron form	Ferric maltol complex	Ferrous salt	Injectable iron complex
Administration	Oral capsule	Oral tablet, capsule, or liquid	Infusion or injection
Manufacturing complexity	Moderate	Low	High
Acquisition cost	Premium oral product	Low-cost generic	High
Main value proposition	Oral iron with differentiated tolerability and absorption profile	Established, inexpensive replacement	Rapid or reliable repletion when oral therapy fails
Excipient opportunity	Stability, shell, wetting, adherence	Cost and taste optimization	Parenteral safety and container compatibility
Generic risk	Patent- and ANDA-dependent	Mature generic market	Complex injectable competition

ACCRUFER's commercial positioning depends on avoiding a direct price comparison with commodity ferrous sulfate. Its defensible segment is patients for whom conventional oral iron is poorly tolerated, ineffective, or clinically inconvenient before intravenous therapy is used.

What manufacturing and IP barriers protect ACCRUFER?

The most relevant barriers are technical execution and clinical positioning.

Manufacturing barriers

Ferric maltol production and encapsulation require control of:

• Complex identity and stoichiometry.
• Residual solvents.
• Particle-size distribution.
• Moisture exposure.
• Blend uniformity.
• Capsule-fill weight.
• Dissolution.
• Elemental impurities.
• Long-term chemical stability.

These barriers are meaningful but not equivalent to the barriers associated with biologics or sterile injectables. A capable generic manufacturer may reproduce the product if the active ingredient, process, analytical methods, and regulatory requirements are sufficiently understood.

IP barriers

The strongest potential barriers are claims that capture ferric maltol itself, clinically relevant treatment methods, or manufacturing features that a generic cannot readily avoid. Conventional excipient claims are less likely to block entry if a generic can use a different disintegrant, lubricant, surfactant, or capsule shell while meeting bioequivalence and quality requirements.

What licensing and commercial opportunities exist?

Shield Therapeutics has used regional commercialization and licensing arrangements for ferric maltol outside its direct commercial footprint. The commercial model can support several transaction types:

• Regional rights for ACCRUFER or Feraccru.
• Co-promotion with nephrology or gastroenterology specialists.
• Specialty-pharmacy distribution.
• Hospital and integrated-delivery-network contracts.
• Authorized-generic arrangements.
• Reformulation licenses.
• Pediatric or dysphagia-focused lifecycle products.
• Co-development with excipient or capsule suppliers.

The strongest licensing proposition is a product that expands use without undermining the current capsule. A sprinkle formulation, lower-burden dosing schedule, or disease-specific presentation could generate differentiated rights. A simple excipient swap with no clinical or regulatory advantage is less likely to justify a material license.

What is the revenue exposure and competitive outlook?

ACCRUFER's revenue exposure is concentrated in the premium oral-iron segment. Key commercial variables are:

• Persistence versus ferrous salts.
• Conversion from intravenous iron.
• Reimbursement and prior authorization.
• Prescriber concentration in nephrology and gastroenterology.
• Patient copay.
• Generic entry timing.
• Regional licensing performance.
• Cost of sales and manufacturing scale.

The product has greater exposure to reimbursement pressure than to biosimilar competition. Its principal threat is a lower-priced generic ferric maltol product or a branded oral iron alternative with comparable tolerability. Intravenous iron remains the higher-cost clinical comparator, while ferrous sulfate remains the lower-cost economic comparator.

Key Takeaways

• ACCRUFER is a 30 mg elemental-iron immediate-release ferric maltol capsule.
• Its excipient strategy is conventional but technically sensitive to moisture, wetting, dissolution, and complex stability.
• The best excipient opportunities involve low-moisture materials, alternate capsule shells, surfactant replacement, second-source supply, and patient-friendly dosage forms.
• NCE exclusivity expired in 2024; remaining generic barriers depend on active patents, Orange Book listings, litigation, and settlements.
• ACCRUFER is exposed to generic substitution, not biosimilar competition.
• Patent strength is likely greater around ferric maltol, therapeutic use, and manufacturing than around routine capsule excipients.
• Commercial growth depends on differentiated tolerability, reimbursement access, specialty prescribing, and lifecycle formulations.

FAQs

Can ACCRUFER be reformulated with a vegetarian capsule?

Yes. A gelatin-to-HPMC conversion is technically plausible, but it would require compatibility, moisture-transfer, dissolution, stability, and regulatory comparability work.

Could a generic avoid ACCRUFER patents by changing the excipients?

Possibly, but only if the substituted formulation falls outside the issued claims and satisfies FDA bioequivalence and quality requirements. Excipients alone do not determine patent clearance.

Is ferric maltol suitable for a pediatric formulation?

Potentially. Multiparticulates, sprinkle products, or lower-strength units could address swallowing and dose-flexibility problems, but pediatric safety, dosing, palatability, and regulatory requirements would control development.

Does ACCRUFER have biosimilar protection?

No. Ferric maltol is a small-molecule active ingredient. Competitors would generally pursue the ANDA generic pathway rather than a biosimilar application.

Which excipient suppliers are best positioned for ACCRUFER lifecycle work?

Suppliers with pharmaceutical-grade HPMC capsules, low-peroxide excipients, controlled moisture specifications, direct-compression grades, and global regulatory documentation are best positioned for reformulation and second-source programs.

References

1. U.S. Food and Drug Administration. (2019). ACCRUFER (ferric maltol) capsules, prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. Shield Therapeutics plc. (2024). Annual report and accounts.
4. European Medicines Agency. (2016). Feraccru: EPAR - product information.
5. U.S. Code, 21 U.S.C. § 355(j). (2024). Abbreviated new drug applications and patent certifications.